Juvenescence Chairman explains why investing in longevity has the potential to deliver significant financial, personal and humanitarian returns.

Jim Mellon, Juvenescence Chairman, explains why investing in longevity has the potential to deliver significant financial, personal and humanitarian returns.

“There’s a lot of great stuff happening, but it’s not one drug that’s going to keep you alive another 10 years in good health, it’s going to be a combination of therapies,” he adds. “And if we can get two or three of those therapies out of clinical trials and into the market, then we’re going to have a very big business indeed and we’re pretty confident we’re going to get there.”

Read the full Longevity Technology article here.